1. Observed RW, modeled, and published trial estimates of HbA1c change from baseline.
Observed RW, modeled, and published trial estimates of HbA1c change from baseline. The addition of other type 2 diabetes medications post index reduced the efficacy gap by 17% for GLP-1 RA (A) and 5% for DPP-4 (B). Adherence in RCTs was assumed to be 95%. aBaseline patient characteristics include age, baseline HbA1c, drug therapy, and any diabetes complications. bTrial change in HbA1c reported in Garber et al. (28). cTrial change in HbA1c reported in Blevins et al. (27). dTrial change in HbA1c reported in Arechavaleta et al. (32). eTrial change in HbA1c reported in Pratley et al. (19).
Ginger S. Carls et al. Dia Care 2017;40:
©2017 by American Diabetes Association